British Journal of Haematology

(The median citation count of British Journal of Haematology is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-06-01 to 2024-06-01.)
COVID‐19‐associated immune thrombocytopenia129
Persisting SARS‐CoV‐2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature118
COVID‐19 and ABO blood group: another viewpoint100
Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma99
Von Willebrand factor propeptide in severe coronavirus disease 2019 (COVID‐19): evidence of acute and sustained endothelial cell activation92
SARS‐CoV‐2‐induced remission of Hodgkin lymphoma92
The association between severe COVID‐19 and low platelet count: evidence from 31 observational studies involving 7613 participants91
Azacitidine for patients with Vacuoles, E1 Enzyme, X‐linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry89
Real‐world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID‐19 disease) in patients with multiple myeloma receiving systemic anti‐ca85
Is molecular mimicry the culprit in the autoimmune haemolytic anaemia affecting patients with COVID‐19?82
Practical guidance for the management of adults with immune thrombocytopenia during the COVID‐19 pandemic82
Poor outcome and prolonged persistence of SARS‐CoV‐2 RNA in COVID‐19 patients with haematological malignancies; King's College Hospital experience81
Updates on targeted therapies for acute myeloid leukaemia81
Increased CD95 (Fas) and PD‐1 expression in peripheral blood T lymphocytes in COVID‐19 patients78
Clinical outcome of coronavirus disease 2019 in haemato‐oncology patients75
Disseminated intravascular coagulation: epidemiology, biomarkers, and management73
T‐cell immune response after mRNA SARS‐CoV‐2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies72
Expert review on soft‐tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations70
Impact of COVID‐19 on red blood cell rheology69
Exacerbation of immune thrombocytopenia following COVID‐19 vaccination69
Hemophagocytic lymphohistiocytosis‐like toxicity (carHLH) after CD19‐specific CAR T‐cell therapy67
Dynamic relationship between D‐dimer and COVID‐19 severity65
Clinical characteristics, management and outcome of COVID‐19‐associated immune thrombocytopenia: a French multicentre series65
Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma65
Chimeric antigen receptor (CAR) natural killer (NK)‐cell therapy: leveraging the power of innate immunity64
Machine learning and artificial intelligence in haematology64
Guidelines on the use of irradiated blood components62
Emicizumab treatment and monitoring in a paediatric cohort: real‐world data62
COVID‐19 infection and sickle cell disease: a UK centre experience61
Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID‐1958
Prevalence of venous thromboembolism in critically ill patients with COVID‐1956
COVID‐19 elicits an impaired antibody response against SARS‐CoV‐2 in patients with haematological malignancies55
Clinical outcomes and risk factors for severe COVID‐19 in patients with haematological disorders receiving chemo‐ or immunotherapy55
Molecular profiling in diffuse large B‐cell lymphoma: why so many types of subtypes?54
First COVID‐19 maternal mortality in the UK associated with thrombotic complications54
Delayed‐phase thrombocytopenia in patients with coronavirus disease 2019 (COVID‐19)52
Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma50
COVID‐19‐induced endotheliitis: emerging evidence and possible therapeutic strategies49
Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) induces neutralising antibody and polyfunctional T‐cell responses in patients with chronic mye49
COVID‐19 mortality in patients on anticoagulants and antiplatelet agents48
Serological SARS‐CoV‐2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID‐19 vaccine in haematological and oncological patients48
Immunogenicity and safety of the BNT162b2 mRNA COVID‐19 vaccine in haematopoietic stem cell transplantation recipients48
Thrombocytopenia is independently associated with poor outcome in patients hospitalized for COVID‐1947
Efficacy of therapeutic plasma exchange in severe COVID‐19 patients46
Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising ant46
Vacuoles in neutrophil precursors in VEXAS syndrome: diagnostic performances and threshold46
A national service for delivering CD19 CAR‐Tin large B‐cell lymphoma – The UK real‐world experience46
Vaccine‐induced immune thrombotic thrombocytopenia (VITT) – a novel clinico‐pathological entity with heterogeneous clinical presentations45
ABO phenotype and death in critically ill patients with COVID‐1944
MYD88 L265P mutation and interleukin‐10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a pros44
Non‐myeloablative human leukocyte antigen‐matched related donor transplantation in sickle cell disease: outcomes from three independent centres43
Graft‐versus‐host disease risk after chimeric antigen receptor T‐cell therapy: the diametric opposition of T cells43
Early mortality benefit with COVID‐19 convalescent plasma: a matched control study42
Cold agglutinin autoimmune haemolytic anaemia associated with novel coronavirus (COVID‐19)42
Haemophagocytic lymphohistiocytosis and Epstein–Barr virus: a complex relationship with diverse origins, expression and outcomes42
COVID‐19 and immunothrombosis: emerging understanding and clinical management41
Convalescent plasma for persisting COVID‐19 following therapeutic lymphocyte depletion: a report of rapid recovery41
Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open‐label Phase II study41
Updated results of the placebo‐controlled, phase III JAKARTA trial of fedratinib in patients with intermediate‐2 or high‐risk myelofibrosis40
Evans syndrome in a patient with COVID‐1939
A left shift in the oxyhaemoglobin dissociation curve in patients with severe coronavirus disease 2019 (COVID‐19)39
Re The source of elevated plasma D‐dimer levels in COVID‐19 infection39
Fostamatinib is an effective second‐line therapy in patients with immune thrombocytopenia38
COVID‐19 in bone marrow transplant recipients: reflecting on a single centre experience37
Clinical outcome and prognostic factors of patients with Richter syndrome: real‐world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC)37
Secondary HLH is uncommon in severe COVID‐1937
Guidelines on the laboratory aspects of assays used in haemostasis and thrombosis37
A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia37
Haematological management of major haemorrhage: a British Society for Haematology Guideline37
Terminal complement inhibition dampens the inflammation during COVID‐1937
Eltrombopag added to immunosuppression for children with treatment‐naïve severe aplastic anaemia36
Physiological and pathophysiological mechanisms of hepcidin regulation: clinical implications for iron disorders36
Thrombophilia testing: A British Society for Haematology guideline36
Risk factors for a severe form of COVID‐19 after allogeneic haematopoietic stem cell transplantation: a Société Francophone de Greffe de Moelle et de Thérapie cellulaire (SFGM‐TC) multicentre cohort s35
Mantle cell lymphoma – advances in molecular biology, prognostication and treatment approaches35
C1 esterase inhibitor and the contact system in COVID‐1935
Haemoglobin oxygen affinity in patients with severe COVID‐19 infection35
Anti‐A isohaemagglutinin titres and SARS‐CoV‐2 neutralization: implications for children and convalescent plasma selection34
The prevention of central nervous system relapse in diffuse large B‐cell lymphoma: a British Society for Haematology good practice paper34
Efficacy and safety of heterologous booster vaccination with Ad26.COV2.S after BNT162b2 mRNA COVID‐19 vaccine in haemato‐oncological patients with no antibody response34
Immune thrombocytopenic purpura after SARS‐CoV‐2 vaccine34
Interleukin‐1 blockade with anakinra in acute leukaemia patients with severe COVID‐19 pneumonia appears safe and may result in clinical improvement34
Identification of CXCL12‐abundant reticular cells in human adult bone marrow34
Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study33
Acquired severe aplastic anaemia: how medical therapy evolved in the 20th and 21st centuries33
Thrombocytopenia as an initial manifestation of COVID‐19; case series and literature review33
Phase II study of azacitidine with pembrolizumab in patients with intermediate‐1 or higher‐risk myelodysplastic syndrome33
Patients with sickle cell disease and suspected COVID‐19 in a paediatric intensive care unit33
Ruxolitinib for tocilizumab‐refractory severe COVID‐19 infection32
Hydroxyurea treatment and neurocognitive functioning in sickle cell disease from school age to young adulthood32
Adjuvant tyrosine kinase inhibitor therapy improves outcome for children and adolescents with acute lymphoblastic leukaemia who have an ABL‐class fusion32
Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real‐world analysis of outcomes in 211 patients32
Integrating germline variant assessment into routine clinical practice for myelodysplastic syndrome and acute myeloid leukaemia: current strategies and challenges32
Anticoagulation with argatroban in patients with acute antithrombin deficiency in severe COVID‐1932
Diagnosis and management of Waldenström macroglobulinaemia—A British Society for Haematology guideline32
Thrombosis in immune thrombocytopenia — current status and future perspectives32
p53 is associated with high‐risk and pinpointsTP53missense mutations in mantle cell lymphoma32
COVID‐19 vaccine failure in chronic lymphocytic leukaemia and monoclonal B‐lymphocytosis; humoural and cellular immunity31
Application of the LymphGen classification tool to 928 clinically and genetically‐characterised cases of diffuse large B cell lymphoma (DLBCL)31
Long‐term efficacy of first‐line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials31
Relative expansion of CD19‐negative very‐early normal B‐cell precursors in children with acute lymphoblastic leukaemia after CD19 targeting by blinatumomab and CAR‐T cell therapy: implications for flo31
Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy31
How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML)31
6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival31
Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience31
Pembrolizumab in relapsed or refractory Richter syndrome30
Subgroup analysis of ICARIA‐MM study in relapsed/refractory multiple myeloma patients with high‐risk cytogenetics30
Allogeneic haematopoietic stem cell transplantation for VEXAS syndrome: UK experience30
Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1‐mutated acute myeloid leukaemia30
Management of sickle cell disease in pregnancy. A British Society for Haematology Guideline29
Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non‐Hodgkin lymphoma29
Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) wi29
Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease29
Amelioration of COVID‐19‐related cytokine storm syndrome: parallels to chimeric antigen receptor‐T cell cytokine release syndrome29
Impaired antibody response to COVID‐19 vaccination in patients with chronic myeloid neoplasms28
Guideline for the laboratory diagnosis of iron deficiency in adults (excluding pregnancy) and children28
Prevalence and mortality in β‐thalassaemias due to outbreak of novel coronavirus disease (COVID‐19): the nationwide Iranian experience28
Pathogenesis of follicular lymphoma: genetics to the microenvironment to clinical translation28
Temporal changes in immune blood cell parameters in COVID‐19 infection and recovery from severe infection27
More on ‘Association between ABO blood groups and risk of SARS‐CoV‐2 pneumonia’27
Lenalidomide and pomalidomide potently interfere with induction of myeloid‐derived suppressor cells in multiple myeloma27
Atypical lymphocytes in peripheral blood of patients with COVID‐1927
von Willebrand factor/ADAMTS13 axis and venous thromboembolism in moderate‐to‐severe COVID‐19 patients27
How we(’ll) treat paroxysmal nocturnal haemoglobinuria: diving into the future27
Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study27
Impact of major bleeding and thrombosis on 180‐day survival in patients with severe COVID‐19 supported with veno‐venous extracorporeal membrane oxygenation in the United Kingdom: a multicentre observa26
Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide26
A universal anti‐Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validation26
Ruxolitinib‐combined doxorubicin‐etoposide‐methylprednisolone regimen as a salvage therapy for refractory/relapsed haemophagocytic lymphohistiocytosis: a single‐arm, multicentre, phase 2 trial26
Immature platelets as a biomarker for disease severity and mortality in COVID‐19 patients26
Are mushroom‐shaped erythrocytes an indicator of COVID‐19?26
Early relapse after high‐dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high‐risk disease in multiple myeloma26
FDG‐PET/CT after two cycles of R‐CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome – final result of a UK National Cancer Research Institute pro26
Managing sickle cell patients with COVID‐19 infection: the need to pool our collective experience25
Varying presentations and favourable outcomes of COVID‐19 infection in children and young adults with sickle cell disease: an additional case series with comparisons to published cases25
Haemophagocytosis in bone marrow aspirates in patients with COVID‐1925
Retention of functional mitochondria in mature red blood cells from patients with sickle cell disease25
Haematological cancers and the risk of severe COVID‐19: Exploration and critical evaluation of the evidence to date25
Zanubrutinib for treatment‐naïve and relapsed/refractory chronic lymphocytic leukaemia: long‐term follow‐up of the phase I/II AU‐003 study25
Efficacy and safety of romiplostim in refractory aplastic anaemia: a Phase II/III, multicentre, open‐label study25
Abnormal concentration of porphyrins in serum from COVID‐19 patients24
Effect of low or high doses of low‐molecular‐weight heparin on thrombin generation and other haemostasis parameters in critically ill patients with COVID‐1924
The changing therapeutic landscape, burden of disease, and unmet needs in patients with cutaneous T‐cell lymphoma24
Second primary malignancy in myelofibrosis patients treated with ruxolitinib24
Rituximab‐treated patients with lymphoma develop strong CD8 T‐cell responses following COVID‐19 vaccination24
COVID‐19 associated Kikuchi‐Fujimoto disease24
Clinical significance of blue‐green neutrophil and monocyte cytoplasmic inclusions in SARS‐CoV‐2 positive critically ill patients23
The role of high‐dose melphalan with autologous stem‐cell transplant in multiple myeloma: is it time for a paradigm shift?23
Eltrombopag second‐line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off‐treatment: results of a phase II, multicentre, prospective study23
Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients23
Vasculo‐toxic and pro‐inflammatory action of unbound haemoglobin, haem and iron in transfusion‐dependent patients with haemolytic anaemias23
Guidelines on the diagnosis, investigation and initial treatment of myeloma: a British Society for Haematology/UK Myeloma Forum Guideline23
Current and future therapies for haemophilia—Beyond factor replacement therapies23
Safety and antibody response after one and/or two doses of BNT162b2 Anti‐SARS‐CoV‐2 mRNA vaccine in patients treated by CAR T cells therapy23
Knowledge gaps in reproductive and sexual health in girls and women with sickle cell disease23
Absence of hydroxyurea‐induced mutational effects supports higher utilisation for the treatment of sickle cell anaemia23
Allogeneic cord blood transfusions prevent fetal haemoglobin depletion in preterm neonates. Results of the CB‐TrIP study22
COVID‐19 infection in patients on anti‐complement therapy: The Leeds National Paroxysmal Nocturnal Haemoglobinuria service experience22
Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response‐adapted design in the first‐line treatment of patients with classical Hodgkin lymphoma unsuita22
Adoptive immunotherapy with double‐bright (CD56bright/CD16bright) expanded natural killer cells in patients with relapsed or refractory acute myeloid leukaemia: a proof‐of‐concep22
Philadelphia‐positive acute lymphoblastic leukaemia (ALL) in Italy during the COVID‐19 pandemic: a Campus ALL study22
Thrombolysis restores perfusion in COVID‐19 hypoxia22
Real‐world non‐interventional long‐term post‐authorisation safety study of ruxolitinib in myelofibrosis21
Inherited predisposition to haematopoietic malignancies: overcoming barriers and exploring opportunities21
Thrombotic thrombocytopenic purpura temporally associated with BNT162b2 vaccination in an adolescent successfully treated with caplacizumab21
Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand‐1 (PD‐L1) expression and increases anti‐tumour effects of T cells in multiple myeloma21
Implications of detecting serum monoclonal protein by MASS‐fix following stem cell transplantation in multiple myeloma20
Co‐morbidities and mortality associated with transfusion‐dependent beta‐thalassaemia in patients in England: a 10‐year retrospective cohort analysis20
Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study*20
Reflection on passive immunotherapy in those who need most: some novel strategic arguments for obtaining safer therapeutic plasma or autologous antibodies from recovered COVID‐19 infected patients20
Third dose of COVID‐19 vaccine restores immune response in patients with haematological malignancies after loss of protective antibody titres20
Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID‐19: disease control as an important factor relative to recent chemotherapy or anti‐CD20 therapy20
Recommendations on prevention of infections during chimeric antigen receptor T‐cell and bispecific antibody therapy in multiple myeloma20
CAR‐T TREK through the lymphoma universe, to boldly go where no other therapy has gone before20
The role of eosinophil morphology in distinguishing between reactive eosinophilia and eosinophilia as a feature of a myeloid neoplasm20
Gender‐related differences in the outcomes and genomic landscape of patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes20
The NICE COVID‐19 rapid guideline on haematopoietic stem cell transplantation: development, implementation and impact20
Safety of anti‐SARS‐CoV‐2 vaccination for patients with immune thrombocytopenia20
Remdesivir during induction chemotherapy for newly diagnosed paediatric acute lymphoblastic leukaemia with concomitant SARS‐CoV‐2 infection20
Serological response following BNT162b2 anti‐SARS‐CoV‐2 mRNA vaccination in haematopoietic stem cell transplantation patients20
Efficacy and safety of intravitreal methotrexate for vitreo‐retinal lymphoma – 20 years of experience20
Cerebral MRI findings predict the risk of cognitive impairment in thrombotic thrombocytopenic purpura20
Glucocorticoid use and risk of first and recurrent venous thromboembolism: self‐controlled case‐series and cohort study20
Epstein–Barr virus status of sporadic Burkitt lymphoma is associated with patient age and mutational features20
Direct‐acting antiviral agents for hepatitis C virus‐mixed cryoglobulinaemia: dissociated virological and haematological responses20
Incorporating acalabrutinib, a selective next‐generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies19
Plasma microparticles of intubated COVID‐19 patients cause endothelial cell death, neutrophil adhesion and netosis, in a phosphatidylserine‐dependent manner19
Treatment for pure red cell aplasia after major ABO‐incompatible allogeneic stem cell transplantation: a multicentre study19
Novel therapies for immune thrombocytopenia19
Fatigue in children and adolescents with immune thrombocytopenia19
TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia19
Long‐term safety and efficacy of the anti‐tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: Phase II study results19
First use of the anti‐VWF nanobody caplacizumab to treat iTTP in pregnancy19
Prognostic impact of TP53 mutation in newly diagnosed diffuse large B‐cell lymphoma patients treated in the FIL‐DLCL04 trial19
Interest of a third dose of BNT162b2 anti‐SARS‐CoV‐2 messenger RNA vaccine after allotransplant19
The detection of circulating plasma cells may improve the Revised International Staging System (R‐ISS) risk stratification of patients with newly diagnosed multiple myeloma19
Second allogeneic haematopoietic cell transplantation using HLA‐matched unrelated versus T‐cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia18
Bone marrow involvement and subclonal diversity impairs detection of mutated CXCR4 by diagnostic next‐generation sequencing in Waldenström macroglobulinaemia18
Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent18
Clinical and laboratory diagnosis of heritable platelet disorders in adults and children: a British Society for Haematology Guideline18
Androgen derivatives improve blood counts and elongate telomere length in adult cryptic dyskeratosis congenita18
Paradoxical effect of SARS‐CoV‐2 infection in patients with immune thrombocytopenia18
Donor source and post‐transplantation cyclophosphamide influence outcome in allogeneic stem cell transplantation for GATA2 deficiency18
Rapid screening of COVID‐19 patients using white blood cell scattergrams, a study on 381 patients18
Monoclonal gammopathy and serum immunoglobulin levels as prognostic factors in chronic lymphocytic leukaemia18
COVID‐19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report18
Haemophilia: factoring in new therapies18
Focus on monoclonal antibodies targeting B‐cell maturation antigen (BCMA) in multiple myeloma: update 202118
Daratumumab‐based therapy for patients with monoclonal gammopathy of renal significance18
Humoral response to mRNA‐based COVID‐19 vaccine in patients with myeloid malignancies18
Prevalence of germline GATA2 and SAMD9/9L variants in paediatric haematological disorders with monosomy 718
Guideline for the first‐line management of Classical Hodgkin Lymphoma — A British Society for Haematology guideline18
Medical comorbidities in patients with chronic lymphocytic leukaemia treated with idelalisib: analysis of two large randomised clinical trials18
Real‐world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study18
Fimepinostat (CUDC‐907) in patients with relapsed/refractory diffuse large B cell and high‐grade B‐cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses17
Combined IL‐6 and JAK/STAT inhibition therapy in COVID‐19‐related sHLH, potential game changer17
Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID‐19 pandemic17
L‐DEP regimen salvage therapy for paediatric patients with refractory Epstein‐Barr virus‐associated haemophagocytic lymphohistiocytosis17
Front‐line management of post‐transplantation lymphoproliferative disorder in adult solid organ recipient patients — A British Society for Haematology Guideline17
EBV‐positive HIV‐associated diffuse large B cell lymphomas are characterized by JAK/STAT (STAT3) pathway mutations and unique clinicopathologic features17
Outcome of early treatment of SARS‐CoV‐2 infection in patients with haematological disorders17
Current and emerging therapeutic approaches for T‐cell acute lymphoblastic leukaemia17
Early intracranial haemorrhages in acute promyelocytic leukaemia: analysis of neuroradiological and clinico‐biological parameters17
Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics‐guided dosing can produce sustained and nearly pancellular expression of fetal haemoglobin in children with si17
Early integration of palliative care for patients with haematological malignancies16
Progress in treating chronic granulomatous disease16
Molecular dynamics of targeting CD38 in multiple myeloma16
Heterogeneity in reporting venous thromboembolic phenotypes in COVID‐19: methodological issues and clinical implications16
Clinical significance of TP53 mutations in adult T‐cell leukemia/lymphoma16
Incidence, prevalence and survival in patients with Langerhans cell histiocytosis: A national registry study from England, 2013–201916
A case of severe aplastic anaemia after SARS‐CoV‐2 vaccination16
Medical therapy to attenuate fetal anaemia in severe maternal red cell alloimmunisation16
A case series of Monoclonal Gammopathy of Undetermined Significance and COVID‐1916
Gene therapy for primary immunodeficiencies16
Measurement of long‐term iron absorption and loss during iron supplementation using a stable isotope of iron (57Fe)16
Clinico‐biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation16
Unanswered questions in cancer‐associated thrombosis16
Outcomes of relapsed/refractory diffuse large B‐cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line—A population‐based study of 736 patients16
Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase‐2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts16
Venetoclax plus hypomethylating agent in blast‐phase myeloproliferative neoplasm: preliminary experience with 12 patients16
Safety and efficacy of daratumumab in patients with multiple myeloma and severe renal failure16
Serum brain‐derived neurotrophic factor (BDNF) concentration predicts polyneuropathy and overall survival in multiple myeloma patients16
SLN124, a GalNac‐siRNA targeting transmembrane serine protease 6, in combination with deferiprone therapy reduces ineffective erythropoiesis and hepatic iron‐overload in a mouse model of β‐thalassaemi16
Haemoglobin response to senicapoc in patients with sickle cell disease: a re‐analysis of the Phase III trial15
Management of cardiovascular complications of bruton tyrosine kinase inhibitors15
Low seropositivity and suboptimal neutralisation rates in patients fully vaccinated against COVID‐19 with B‐cell malignancies15
Myeloma patients with COVID‐19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccine15
Role of bone marrow‐derived mesenchymal stem cell defects in CD8+CD28 suppressor T‐lymphocyte induction in patients with immune thrombocytopenia and associated mechanisms15
Maternal and neonatal outcomes in 80 patients diagnosed with non‐Hodgkin lymphoma during pregnancy: results from the International Network of Cancer, Infertility and Pregnancy15
The 12‐week kinetics of anti‐SARS‐CoV‐2 antibodies in different haematological cancers after vaccination with BNT162b215